A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Inclusion Criteria:
Exclusion Criteria:
CABA, C1192AAW, Argentina
Ciudad de Buenos Aires, 1015, Argentina
Ciudad de Buenos Aires, 1181, Argentina
Ciudad de Buenos Aires, AR-CP 1221, Argentina
Higashimatsuyama-shi, 355-0005, Japan
Isehara-shi, 259-1193, Japan
Itabashi-ku, 173-8610, Japan
Kawasaki-shi, 216-8511, Japan
Shinjuku-ku, 160-0023, Japan
Shinjuku-ku, 160-8582, Japan
Suita-shi, 565-0871, Japan